Skip to main content
. 2018 Nov 2;3(21):e123578. doi: 10.1172/jci.insight.123578

Figure 2. Arhgef12 is necessary for IL17A-induced RhoA activation and airway hypercontractility.

Figure 2

(A and B) Western blot for phosphorylated myosin light chain in Arhgef12–/– and WT mouse tracheal lysates and WT mouse tracheal lysates treated with or without Arhgef12 inhibitor Y16, with densitometry (n = 4 mice per condition; veh, DMSO; *P < 0.05, **P < 0.01 by 1-tailed Student’s t test; box plots show minimum, maximum, and median with 25th to 75th percentile range). (C) ELISA for Rhotekin-rho–binding domain affinity-captured active RhoA (n = 5 mice per condition; *P < 0.05 by 1-tailed Student’s t test; box plots show minimum, maximum, and median with 25th to 75th percentile range).). (D and E) Methacholine-induced (Mch-induced) contractile force of tracheal rings treated with IL17A (n = 4 rings per group; *P < 0.05, **P < 0.001, ***P < 0.0001 by Tukey’s multiple comparisons test following 2-way ANOVA for Il17A-treated comparing WT versus Arhgef12–/– or vehicle versus Y16; data are mean ± SEM).